Literature DB >> 21172195

European evidence-based Consensus on the management of ulcerative colitis: Current management.

S P L Travis, E F Stange, M Lémann, T Oresland, W A Bemelman, Y Chowers, J F Colombel, G D'Haens, S Ghosh, P Marteau, W Kruis, N J McC Mortensen, F Penninckx, M Gassull.   

Abstract

Entities:  

Year:  2008        PMID： 21172195     DOI： 10.1016/j.crohns.2007.11.002

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


× No keyword cloud information.
  90 in total

Review 1.  MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis.

Authors:  Lily P H Yang; Paul L McCormack
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.

Authors:  Javier P Gisbert; María Chaparro; Fernando Gomollón
Journal:  World J Gastroenterol       Date:  2011-08-14       Impact factor: 5.742

3.  Immunomodulators for all patients with inflammatory bowel disease?

Authors:  Sandro Ardizzone; Andrea Cassinotti; Gianpiero Manes; Gabriele Bianchi Porro
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

4.  Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.

Authors:  Gabriele Stocco; Eva Cuzzoni; Sara De Iudicibus; Diego Favretto; Noelia Malusà; Stefano Martelossi; Elena Pozzi; Paolo Lionetti; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 5.  Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.

Authors:  Antonio Di Sabatino; Lucio Liberato; Monia Marchetti; Paolo Biancheri; Gino R Corazza
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

6.  Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study.

Authors:  Nobuo Hiwatashi; Yasuo Suzuki; Keiichi Mitsuyama; Akihiro Munakata; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2010-09-29       Impact factor: 7.527

7.  Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients.

Authors:  Natalia Sutiman; Sylvia Chen; Khoon Lin Ling; Sai Wei Chuah; Wai Fook Leong; Vinayak Nadiger; Madeline Tjai; Chris San Choon Kong; Brian John Schwender; Webber Chan; Hang Hock Shim; Wee Chian Lim; Chiea Chuen Khor; Yin Bun Cheung; Balram Chowbay
Journal:  Pharmacogenomics       Date:  2017-12-06       Impact factor: 2.533

Review 8.  Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Raul Raz; Walid Saliba
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

9.  Steroids and 5-aminosalicylic acids in moderate ulcerative colitis: addressing the dilemma.

Authors:  Chris Probert
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

10.  Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies.

Authors:  Fernando Bermejo; Javier P Gisbert
Journal:  Ther Adv Chronic Dis       Date:  2010-05       Impact factor: 5.091
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.